Safe Biologics

The bill creates a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation. Representatives Eshoo and Inslee were the lead sponsors of two separate biosimilar bills during the 110th Congress, and now have one bill with Rep. Barton, ranking member of the Energy and Commerce Committee, to bring congressional stakeholders and interested parties to bipartisan consensus with this joint legislation.
Read More

The bill creates a process for approval of “biosimilars” or “follow-on biologics” while protecting patient health and safety, lowering health care costs, and providing adequate incentives for innovation. Representatives Eshoo and Inslee were the lead sponsors of two separate biosimilar bills during the 110th Congress, and now have one bill with Rep. Barton, ranking member of the Energy and Commerce Committee, to bring congressional stakeholders and interested parties to bipartisan consensus with this joint legislation.
Read More

One somewhat overlooked element of the Obama administration’s proposed federal budget is its desire to create the first regulatory process for government approval of so-called “follow-on biologics,” or generic versions of drugs manufactured by living organisms. These medicines are often used in treatments such as cancer, anemia, psoriasis and rare diseases, where little room for error exists.
Read More

At a time when cancer and heart disease are the nation’s and the world’s top killers, biopharmaceutical research companies headquartered in California are developing 243 of the 1,186 medicines in development for those dreaded diseases.
Read More

At a time when cancer and heart disease are the nation’s and the world’s top killers, biopharmaceutical research companies headquartered in California are developing 243 of the 1,186 medicines in development for those dreaded diseases.
Read More

October 27, 2011
Embassy Suites Dublin
Dublin, OH
Read More

BioOhio
BioEnterprise Corporation, Cleveland
BioStart
Edison Biotechnology Institute – Ohio University TechColumbus
Office of Governor John Kasich
Ohio Department of Health
Ohio House of Representatives
Ohio State Legislature
Ohio State Medical Association
Ohio State Senate

BioOhio represents and advocates for Ohio’s bioscience community to improve business environment and public funding climate. Alone or in conjunction with partners and members, BioOhio pursues both a proactive and responsive advocacy program.
Read More

In Business Facilities Magazine’s 2009 Biotechnology Strength Report released last fall, Ohio is once again ranked fourth among all states. California claimed top ranking, followed by Massachusetts, Pennsylvania, and Ohio.  Maryland, Texas, New Jersey, Illinois, Kansas, and North Carolina rounded out the top 10.
Read More